IVVD — Invivyd, Inc.

Invivyd (IVVD) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue Growth: Q3 2025 revenues increased by 11% quarter-over-quarter and 41% year-over-year, indicating strong market awareness and adoption.
• Capital Raise: Invivyd raised approximately $87 million in capital during the quarter, enhancing its financial position to support ongoing and future clinical programs.
• Cash Position: The company reported a significantly improved cash position, allowing for continued operational discipline and funding for pivotal studies.

2. Strategic Updates and Business Highlights

• PEMGARDA Franchise: Continued growth in the PEMGARDA commercial franchise, with over 15,000 contracted GPO sites and 76% reorder rates from infusion centers.
• VYD2311 Development: Received FDA feedback to develop VYD2311, a next-generation antibody for broader COVID-19 prevention, with pivotal studies expected to start by year-end 2025 and top-line data anticipated in mid-2026.
• Clinical Studies: Plans to conduct the LIBERTY study to compare VYD2311 against mRNA vaccines, focusing on safety and efficacy, particularly for vulnerable populations.

3. Forward Guidance and Outlook

• Pivotal Program Initiation: The pivotal program for VYD2311 is on track to begin by the end of 2025, with expectations for significant data release in mid-2026.
• Market Potential: Invivyd sees a substantial near-term commercial opportunity, projecting a potential market for VYD2311 that could rival existing COVID vaccine sales, which totaled $3.8 billion in the U.S. last year.

4. Bad News, Challenges, or Points of Concern

• Regulatory Coordination: There are complexities regarding the coordination between CBER and CDER for the LIBERTY study, which could introduce delays or uncertainties in the approval process.
• Market Competition: The company acknowledges the existing competition from established COVID vaccines and the skepticism surrounding vaccine uptake, particularly concerning safety concerns that may hinder broader acceptance.

5. Notable Q&A Insights

• PEMGARDA Future: Management clarified that they do not plan to wind down PEMGARDA even if VYD2311 is approved, as it remains a differentiated product.
• Commercial Strategy: The team is expanding beyond infusion centers and enhancing digital outreach to increase awareness and adoption of their products.
• Discovery Programs: Discussion on early-stage discovery efforts for RSV and LIBERTY highlighted the potential for differentiation in these markets, with updates expected before the end of the year.

Overall, Invivyd is positioned for growth with its innovative approach to COVID-19 prevention, backed by strong financials and strategic initiatives, while navigating regulatory complexities and market competition.